KUVATRIS THERAPEUTICS, INC. Share-based Payment Arrangement, Expense
KUVATRIS THERAPEUTICS, INC. reported Share-based Payment Arrangement, Expense of $1.51 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2026-01-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-01-14
- KUVATRIS THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- KUVATRIS THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2024-06-30 was $151.00, a 99.99% decline year-over-year.
- KUVATRIS THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2024-03-31 was $1.51M, a 30.28% decline year-over-year.
- KUVATRIS THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2023-09-30 was $1.06M, a 1.70% increase year-over-year.
- KUVATRIS THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2022 was $500.00K, a 61.54% decline from fiscal 2021.
- KUVATRIS THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2021 was $1.30M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-01-14 | $151.00 derived: sum of 2 quarters · filed 2026-01-14 | $1.51M 10-Q · filed 2026-01-14 | |
| 2024-06-30 | $151.00 10-Q · filed 2024-09-20 | $1.51M 10-Q · filed 2024-09-20 | ||
| 2024-03-31 | $1.51M 10-Q · filed 2024-05-13 | |||
| 2023-09-30 | $1.06M 10-Q · filed 2026-01-14 | $2.33M derived: sum of 2 quarters · filed 2026-01-14 | $4.50M 10-Q · filed 2026-01-14 | $3.62M derived: sum of 4 quarters · filed 2026-01-14 |
| 2023-06-30 | $1.26M 10-Q · filed 2024-09-20 | $3.44M 10-Q · filed 2024-09-20 | $2.56M derived: sum of 3 quarters · filed 2024-09-20 | $3.61M derived: sum of 4 quarters · filed 2024-09-20 |
| 2023-03-31 | $2.17M 10-Q · filed 2024-05-13 | $1.29M derived: sum of 2 quarters · filed 2024-05-13 | $2.34M derived: sum of 3 quarters · filed 2024-05-13 | $2.49M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$877.16K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $169.99K derived: sum of 2 quarters · filed 2023-11-16 | $318.81K derived: sum of 3 quarters · filed 2023-11-16 | $500.00K 10-K · filed 2023-03-30 |
| 2022-09-30 | $1.05M 10-Q · filed 2023-11-16 | $1.20M derived: sum of 2 quarters · filed 2023-11-16 | $1.38M 10-Q · filed 2023-11-16 | $1.57M derived: sum of 4 quarters · filed 2023-11-16 |
| 2022-06-30 | $148.82K 10-Q · filed 2023-08-09 | $330.01K 10-Q · filed 2023-08-09 | $519.14K derived: sum of 3 quarters · filed 2023-08-09 | $791.26K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $181.19K 10-Q · filed 2023-05-15 | $370.32K derived: sum of 2 quarters · filed 2023-05-15 | $642.44K derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $189.13K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $461.25K derived: sum of 2 quarters · filed 2023-03-30 | $1.30M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $272.12K 10-Q · filed 2022-11-14 | $1.11M 10-Q · filed 2022-11-14 |